|
|
|
| Therapeutic Effect of Probucol Combined with Rosuvastatin in the Treatment of Carotid Atherosclerotic Plaque in Patients with Cerebral Infarction Complicated with Diabetes |
| SHUDan, CHENTing-yan, LIANGDan |
| Department of Internal Medicine, Xinhua Hospital of Chengdu, Chengdu, Sichuan 610051 |
|
|
|
|
Abstract 【Objective】 To investigate the efficacy of probucol combined with rosuvastatin in the treatment of carotid atherosclerotic plaques in patients with cerebral infarction complicated with type 2 diabetes mellitus (T2DM). 【Methods】 A total of 126 patients with cerebral infarction combined with T2DM who were treated in our hospital from February 2016 to August 2014 were selected as the research subjects. The patients were randomly divided into the observation group and the control group, with 63 cases in each group. Patients in the control group received rosuvastatin alone, while patients in the observation group received ropucol combined with rosuvastatin. Patients in both groups were treated for 1 year. The results of carotid artery ultrasound examination, the indexes of blood lipid and inflammatory factors, protein S100 beta, microalbuminuria, and neurological status determination (NIHSS evaluation) between the two groups were compared before and after treatment. The incidence of adverse reactions was recorded at the same time. 【Results】 After treatment, the carotid intima-media thickness (CAIMT), endometrial plaque area and the detection rate of vulnerable plaque were lower in both groups than those before treatment (P<0.05), and those in the observation group decreased more significantly (P<0.05). After treatment, total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) were lower than those before treatment (P>0.05), while the level of high-density lipoprotein cholesterol (HDL-C) was higher than that before treatment. The changes in the observation group were more remarkable with statistical significance (P<0.05). Levels of protein S100 beta, urinary microalbumin and stroke scale (NIHSS) score, high-sensitivity C-raction protein )hs-CRP), interleukin 6 (IL-6) and tumor necrosis factor (TNF-α) in both groups decreased after treatment (P<0.05), and the decrease in the observation group was more obvious than those in the control group (P<0.05). The incidence of adverse reactions such as headache, dizziness, rash, nausea and vomiting, myalgia, hepatorenal dysfunction and gastrointestinal reactions in the two groups were not statistically different (P>0.05). 【Conclusion】 Probucol combined with rosuvastatin is more effective in the treatment of cerebral infarction with diabetes mellitus. It is worthy of clinical application.
|
|
Received: 07 December 2017
|
|
|
|
|
|
[1] 李永华. 瑞舒伐他汀联合普罗布考治疗颈动脉易损粥样硬化斑块效果评估[J].中外医学研究,2017,15(8):48-50.
[2] 陈林. 保护性早期降压策略对脑卒中急性期患者神经功能恢复及预后的影响[J].医学临床研究, 2017, 34(6):1200-1202.
[3] 黄羽. 马来酸依那普利叶酸片联合亚低温对伴H型高血压缺血性脑卒中患者血管内皮功能、神经功能缺损及预后的影响[J].医学临床研究, 2018, 35(2):284-287.
[4] 张丽丽. 瑞舒伐他汀联合普罗布考在颈动脉粥样硬化斑块治疗中的应用价值[J].临床医学,2016,43(12):70-72.
[5] 谷胜利,邵静,刘改玲,等. 瑞舒伐他汀钙对脑梗死患者颈动脉粥样硬化斑块的疗效及血脂、C反应蛋白水平的影响[J].中国药业,2016,25(17):22-25.
[6] 申丽萍, 侯玉立. 急性缺血性脑卒中患者胆红素水平对NIHSS评分及预后的影响[J].社区医学杂志, 2016, 14(15):48-50.
[7] 陈晓,杨敏,付睿,等. 瑞舒伐他汀联合普罗布考治疗颈动脉易损粥样硬化斑块的疗效临床随机对照研究[J].中国全科医学,2013,16(30):2799-2802.
[8] 刘国勤. 瑞舒伐他汀与普罗布考联合用药在颈动脉粥样硬化斑块治疗中的应用价值[J].中国医学装备,2015,12(8):92-95.
[9] 董晓柳,朱丽霞,徐士军. 普罗布考联合瑞舒伐他汀对脑梗死合并糖尿病患者颈动脉粥样硬化斑块、血脂及炎症因子的影响[J].中国动脉硬化杂志,2016,24(2):177-181.
[10] 王喜福,叶明,李远竞,等. 普罗布考联合瑞舒伐他汀对高脂血症患者颈动脉斑块及炎性因子的影响[J].安徽医药,2013,17(5):836-838.
[11] 许宏侠. 瑞舒伐他汀联合普罗布考对脑梗死患者血脂、颈动脉粥样硬化斑块和hs-CRP的影响[J].中国现代医生,2015,9(15):64-69. |
|
|
|
2018, Vol. 35 
